Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel

Showing results (351-360 of 460) with videos related to

Pageof 46
Sort By:
The Journal of Allergy and Clinical Immunology|August 15, 2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamerThomas J Povsic, Monica G Lawrence, A Michael Lincoff, et al.
Circulation|March 20, 2016
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy StudyIan T Meredith, Jean-François Tanguay, Dean J Kereiakes, et al.
American Heart Journal|March 30, 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategyMarc W Klutstein, Cynthia M Westerhout, Paul W Armstrong, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
Nature Reviews. Disease Primers|June 8, 2019
ST-segment elevation myocardial infarctionBirgit Vogel, Bimmer E Claessen, Suzanne V Arnold, et al.
Lancet (London, England)|August 17, 2010
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialEric J Topol, Marie-Germaine Bousser, Keith A A Fox, et al.
Open Forum Infectious Diseases|November 20, 2025
Clinical, Radiographic, and Physiological Correlates of Post-COVID-19 Dyspnea in Military Health System Beneficiaries: Results From the Chronic Impairment With Pulmonary Symptoms (ChIPS) Sub-studyS Michael Goertzen, David A Lindholm, Robert J Walter, et al.
Circulation|August 26, 2023
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 TestsMichael Szarek, Esther Reijnders, J Wouter Jukema, et al.
Pageof 46

Showing results (351-360 of 460) with videos related to

Sort By:
Pageof 46
The Journal of Allergy and Clinical Immunology|August 15, 2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamerThomas J Povsic, Monica G Lawrence, A Michael Lincoff, et al.
Circulation|March 20, 2016
Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy StudyIan T Meredith, Jean-François Tanguay, Dean J Kereiakes, et al.
American Heart Journal|March 30, 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategyMarc W Klutstein, Cynthia M Westerhout, Paul W Armstrong, et al.
Journal of Thrombosis and Haemostasis : JTH|October 26, 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 yearsNeil A Goldenberg, Sam Schulman, John M Kittelson, et al.
Circulation|April 7, 2022
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER TrialsAlex C Spyropoulos, Gary E Raskob, Alexander T Cohen, et al.
JAMA|June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registryKim A Eagle, Michael J Lim, Omar H Dabbous, et al.
Nature Reviews. Disease Primers|June 8, 2019
ST-segment elevation myocardial infarctionBirgit Vogel, Bimmer E Claessen, Suzanne V Arnold, et al.
Lancet (London, England)|August 17, 2010
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialEric J Topol, Marie-Germaine Bousser, Keith A A Fox, et al.
Open Forum Infectious Diseases|November 20, 2025
Clinical, Radiographic, and Physiological Correlates of Post-COVID-19 Dyspnea in Military Health System Beneficiaries: Results From the Chronic Impairment With Pulmonary Symptoms (ChIPS) Sub-studyS Michael Goertzen, David A Lindholm, Robert J Walter, et al.
Circulation|August 26, 2023
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 TestsMichael Szarek, Esther Reijnders, J Wouter Jukema, et al.
Pageof 46